{"gene":"MARCKS","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1992,"finding":"MARCKS is a filamentous (F)-actin crosslinking protein; this crosslinking activity is inhibited by PKC-mediated phosphorylation and by binding to calcium-calmodulin, establishing MARCKS as a regulated crossbridge between actin and the plasma membrane.","method":"In vitro F-actin crosslinking assay, PKC phosphorylation, calmodulin binding assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro reconstitution of actin crosslinking with defined enzymatic (PKC) and calmodulin inhibition; replicated conceptually across multiple subsequent studies","pmids":["1560845"],"is_preprint":false},{"year":1993,"finding":"MARCKS binds to phospholipid membranes through two sites: the N-terminal myristoyl moiety and the basic phosphorylation domain; phosphorylation of the basic domain by PKC lowers its affinity for negatively charged phospholipids (phosphatidylserine), causing dissociation from membranes.","method":"Purified MARCKS binding to liposomes (phosphatidylcholine and phosphatidylserine), synthetic phosphorylation domain peptide assays, PKC phosphorylation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro with purified protein and defined lipid vesicles; mutagenic dissection using synthetic peptide of phosphorylation domain","pmids":["8486722"],"is_preprint":false},{"year":1991,"finding":"PKC phosphorylation of the MARCKS effector domain peptide at Ser8 and Ser12 (with Ser12 being key) produces a ~200-fold decrease in calmodulin affinity, causing rapid release of bound calmodulin and enabling subsequent calmodulin-dependent enzyme activation.","method":"Synthetic MARCKS effector domain peptide (25-mer), PKC phosphorylation in vitro, calmodulin binding assay, calmodulin-dependent enzyme activity assays (phosphodiesterase, calcineurin, myosin light chain kinase)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — quantitative in vitro reconstitution with synthetic peptide, site-specific phosphorylation mapping, and functional calmodulin release assays","pmids":["2002042"],"is_preprint":false},{"year":1993,"finding":"In rat brain, PKC isoforms I, II, and III phosphorylate MARCKS at Ser152, Ser156, and Ser163, but not at Ser160 as previously reported; Ser152 and Ser156 are phosphorylated at twice the initial rate of Ser163, with no isoform preference.","method":"Tryptic peptide analysis of PKC-phosphorylated MARCKS and synthetic peptide, alpha-chymotrypsin digestion, 32P incorporation mapping","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous in vitro mapping with purified PKC isoforms and peptide analysis, but single laboratory, single method","pmids":["8422248"],"is_preprint":false},{"year":1995,"finding":"PKC-dependent phosphorylation regulates cycling of MARCKS between the plasma membrane and Lamp-1-positive lysosomes in fibroblasts; mutating PKC phosphorylation sites prevents both membrane release and lysosomal targeting, indicating phosphorylation is required for translocation.","method":"Immunofluorescence, immunoelectron microscopy, subcellular fractionation, PKC mutant MARCKS (phosphorylation-deficient), lysosomotropic agents, nocodazole","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (immunofluorescence, immuno-EM, fractionation) with defined phosphorylation-site mutants in intact cells","pmids":["7720702"],"is_preprint":false},{"year":1995,"finding":"MARCKS is required for normal mouse brain development; MARCKS-deficient mice exhibit exencephaly, agenesis of corpus callosum, failure of cerebral hemisphere fusion, and cortical/retinal lamination abnormalities, with all pups dying perinatally.","method":"Homologous recombination gene disruption (knockout mice), histological analysis of embryos and pups","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined developmental phenotypes; replicated and extended in subsequent studies","pmids":["7862670"],"is_preprint":false},{"year":1997,"finding":"Expression of a MARCKS mutant that abrogates the myristoyl-electrostatic switch prevents cell spreading in fibroblasts, arresting cells at an early stage with membrane blebbing and preventing membrane ruffle and lamellae formation, accompanied by decreased cell-substratum adhesion.","method":"Transfection of myristoyl-electrostatic switch mutant MARCKS in fibroblasts, cell morphology analysis, cell adhesion assay","journal":"Current biology : CB","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — structure-function mutant with defined cellular phenotype readouts; single laboratory, two orthogonal measurements (morphology + adhesion)","pmids":["9259558"],"is_preprint":false},{"year":1997,"finding":"Cathepsin B is the cellular MARCKS-cleaving enzyme (MCE); it cleaves MARCKS at the lysosomal compartment to generate a carboxyl-terminal fragment (p40), and specific cathepsin B inhibitor CA074-Me blocks this cleavage in fibroblasts.","method":"Co-purification of MCE activity with cathepsin B immunoreactivity, cell-free cathepsin B cleavage assay, cell-permeable cathepsin B inhibitor (CA074-Me), subcellular fractionation, NH4Cl treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — enzyme identified by co-purification and cell-free reconstitution, confirmed with specific inhibitor in intact cells; single laboratory with multiple orthogonal methods","pmids":["9295331"],"is_preprint":false},{"year":1998,"finding":"The kinetics of MARCKS effector domain peptide binding to phospholipid vesicles is diffusion-limited; Ca2+-calmodulin (5 µM) accelerates removal of the peptide from membranes by ~10-fold (reducing membrane lifetime from 0.1 s to 0.01 s), via a proposed diffusion-limited calmodulin extraction mechanism.","method":"Stopped-flow fluorescence measurements, spin-labeled EPR structure determination of membrane-bound effector peptide","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Moderate — quantitative kinetic measurements with reconstituted system, EPR structural validation, single laboratory with two orthogonal methods","pmids":["9804991"],"is_preprint":false},{"year":1993,"finding":"Okadaic acid-sensitive phosphatases (PP1/PP2A) dephosphorylate MARCKS in intact Swiss 3T3 cells following PKC-mediated phosphorylation; PP1, PP2A, and PP2C can all dephosphorylate MARCKS in cell-free assays.","method":"Cell-free phosphatase assays with PP1, PP2A, PP2C; okadaic acid treatment in intact cells; bombesin-stimulated receptor blockade","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro enzyme assay plus cell-based pharmacological inhibition; single laboratory","pmids":["8262213"],"is_preprint":false},{"year":2003,"finding":"The myristoyl moiety at the MARCKS N-terminus directly participates in calmodulin binding, providing ionic-strength-independent binding that is absent in non-myristoylated MARCKS; phosphorylation-independent calmodulin binding occurs through the N-terminal domain.","method":"Calmodulin-agarose chromatography with myristoylated vs. non-myristoylated recombinant MARCKS, quantitative dansyl-calmodulin binding assay, synthetic myristoylated N-terminal peptide, mutation analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted binding with purified proteins, quantitative affinity measurements, mutagenesis, and synthetic peptide validation; single laboratory with multiple orthogonal methods","pmids":["14506265"],"is_preprint":false},{"year":2004,"finding":"MARCKS bi-directional translocation between membrane and cytosol regulated by alpha5beta1 integrin-activated PKC is required for actin stress fiber formation during muscle cell spreading; PKC-dependent phosphorylation/membrane dissociation enables initial cell adhesion, while subsequent dephosphorylation/membrane return enables actin crosslinking and cytoskeletal maturation.","method":"MARCKS mutants (membrane association-deficient; PKC phosphorylation-deficient) in muscle cells, integrin-fibronectin binding assays, actin staining, cell spreading assays","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — structure-function mutants with defined phenotypes, integrin-specific pathway placement; single laboratory","pmids":["15316066"],"is_preprint":false},{"year":2007,"finding":"PKC-delta (not PKC-epsilon) specifically phosphorylates MARCKS to regulate airway mucin secretion; dominant-negative PKC-delta blocks both MARCKS phosphorylation and mucin hypersecretion, while wild-type PKC-delta overexpression enhances both.","method":"Dominant-negative and wild-type PKC-delta/epsilon constructs transfected into bronchial epithelial cells, PKC-delta selective inhibitor rottlerin, MARCKS phosphorylation assay, mucin secretion assay","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative and wild-type constructs with parallel functional readouts; single laboratory, two orthogonal approaches (genetic + pharmacological)","pmids":["18055557"],"is_preprint":false},{"year":2009,"finding":"MARCKS, via its myristoylated N-terminus, regulates human neutrophil migration and beta2 integrin-dependent adhesion; the MANS peptide (N-terminus mimic) reduces F-actin content after fMLF stimulation without affecting beta2 integrin surface expression.","method":"Cell-permeant MANS peptide treatment of human neutrophils, migration assays (fMLF, IL-8, LTB4), beta2 integrin expression by FACS, F-actin quantification","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific peptide inhibitor with multiple functional readouts; single laboratory","pmids":["19574534"],"is_preprint":false},{"year":2009,"finding":"MARCKS modulates radial glial progenitor placement and proliferation in the developing cerebral cortex; the myristoylation domain (but not PKC phosphorylation sites) is essential for this function, suggesting membrane association is the key requirement for MARCKS role in radial glia.","method":"MARCKS knockout mice, genetic rescue with phosphorylation-deficient and myristoylation-deficient MARCKS mutants, immunostaining for polarity complexes and radial glia markers","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic rescue experiments with defined MARCKS mutants in vivo, dissecting phosphorylation vs. myristoylation requirements; clean KO phenotype with molecular pathway analysis","pmids":["19666823"],"is_preprint":false},{"year":2012,"finding":"MARCKS is identified as a curvature and lipid sensor; the MARCKS effector domain (25-mer peptide) recognizes phosphatidylserine with preference for highly curved vesicles in a sequence-specific manner.","method":"Fluorescence-based lipid binding assays with vesicles of defined curvature and composition, sequence-specific peptide variants","journal":"ACS chemical biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with defined lipid vesicles and systematic sequence variants; single laboratory","pmids":["23075500"],"is_preprint":false},{"year":2012,"finding":"MARCKS mediates H2O2-induced endothelial permeability via a signaling cascade: Rac1 → Abl1 → PLCγ1 → PKCδ → MARCKS phosphorylation and translocation from membrane to cytosol, leading to actin cytoskeleton remodeling.","method":"siRNA knockdown of MARCKS and pathway components, pharmacological inhibitors, MARCKS phosphorylation/translocation assay, permeability assay in bovine aortic endothelial cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established by siRNA at multiple pathway nodes; single laboratory","pmids":["22927426"],"is_preprint":false},{"year":2012,"finding":"MARCKS regulates Xenopus ENaC activity through PIP2-dependent mechanism; MARCKS sequesters PIP2 at the apical membrane, and its phosphorylation (PKC) or calmodulin-mediated dissociation from the membrane reduces PIP2 availability and ENaC open probability; FRET shows close proximity between ENaC and MARCKS when PKC activity is low.","method":"Lipid binding assay, co-immunoprecipitation, confocal microscopy, FRET, transepithelial current measurements, single-channel patch-clamp","journal":"American journal of physiology. Renal physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (co-IP, FRET, patch-clamp); single laboratory","pmids":["22791334"],"is_preprint":false},{"year":2012,"finding":"MARCKS specifically binds LPS via a heptapeptide within its effector domain (determined by NMR); after LPS stimulation MARCKS translocates to FYVE-positive endosomes and co-localizes with LPS; MARCKS deficiency increases TLR4-specific (not TLR2/3/5) LPS signaling.","method":"NMR spectroscopy, LPS binding assay, confocal microscopy (FYVE endosome co-localization), MARCKS-deficient MEFs, siRNA knockdown, MARCKS overexpression, cytokine measurement","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — NMR structure of binding interaction plus genetic (KO MEFs, siRNA, overexpression) functional data; single laboratory with multiple orthogonal methods","pmids":["22427633"],"is_preprint":false},{"year":2013,"finding":"TLC-induced retrieval of MRP2 from the canalicular membrane in hepatocytes involves sequential PKCε activation → MARCKS phosphorylation → MARCKS detachment from membrane; phosphorylation-deficient MARCKS mutant blocks TLC-induced MRP2 retrieval.","method":"Dominant-negative PKCε transfection, phosphorylation-deficient MARCKS mutant transfection, subcellular fractionation (PM fractions), MARCKS phosphorylation assay in HuH-NTCP cells and rat hepatocytes","journal":"Hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (dominant-negative, phosphorylation-dead mutant) plus fractionation; single laboratory","pmids":["23424156"],"is_preprint":false},{"year":2015,"finding":"δ-PKC (not α-, β-, or ζ-PKC) is the specific isoform that phosphorylates MARCKS to regulate human neutrophil migration and adhesion in vitro; rottlerin (δ-PKC inhibitor) attenuates fMLF-induced MARCKS phosphorylation, adhesion, and migration.","method":"PKC isoform-selective inhibitors (rottlerin, Gö6976, others) on human neutrophils, MARCKS phosphorylation assay, migration and adhesion assays","journal":"Inflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological isoform dissection with parallel functional readouts; single laboratory","pmids":["25515270"],"is_preprint":false},{"year":2015,"finding":"Calmodulin binding to the MARCKS effector domain and CaMKII-mediated phosphorylation of filamin both promote dissociation of MARCKS from the apical membrane, reducing ENaC open probability; mutations in MARCKS preventing calmodulin association prevent membrane dissociation.","method":"Calmidazolium (calmodulin inhibitor), KN93 (CaMKII inhibitor), cytochalasin E (actin disruption), ENaC patch-clamp and transepithelial current, MARCKS calmodulin-binding mutants, co-immunoprecipitation","journal":"American journal of physiology. Renal physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple inhibitors and MARCKS mutants with defined electrophysiological readouts; single laboratory","pmids":["26136560"],"is_preprint":false},{"year":2016,"finding":"Ca2+-PKC phosphorylation of MARCKS releases sequestered PIP2, which recruits and activates PI3K on the membrane surface; in the unphosphorylated state MARCKS sequesters PIP2 and inhibits PI3K membrane binding; this Ca2+-PKC-MARCKS-PIP2-PI3K module constitutes a leading-edge amplification circuit.","method":"Single-molecule fluorescence reconstitution on lipid bilayers, surface density measurements of PKC, MARCKS peptide, and PI3K; PKC phosphorylation assay","journal":"Biophysical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted multi-protein signaling pathway on defined lipid bilayers with single-molecule resolution; quantitative mechanistic dissection in vitro, consistent with in vivo data","pmids":["27119641"],"is_preprint":false},{"year":2016,"finding":"In megakaryocytes, dephosphorylated MARCKS promotes proplatelet formation; PKC-mediated MARCKS phosphorylation inhibits proplatelet formation and correlates with Arp2 phosphorylation; MARCKS KO mice show decreased proplatelet levels, and MARCKS inhibition reduces proplatelet formation by 53%.","method":"2D-DIGE proteomics, polysome profiling, MARCKS KO mice, PMA treatment, MARCKS peptide inhibition, Arp2 inhibitor assay, confocal localization","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO, peptide inhibition, and pharmacological manipulation with quantitative proplatelet readout; multiple orthogonal approaches across two laboratories","pmids":["26744461"],"is_preprint":false},{"year":2016,"finding":"A PKC-MARCKS-PI3K regulatory module links leading-edge Ca2+ and PIP3 signals in live macrophages; PKC and PI3K are both essential for the positive feedback loop; activators stimulate leading-edge PKC activity, MARCKS membrane displacement, and increased PIP3, while inhibitors trigger the opposite.","method":"Live-cell biosensors (AKT-PH-mRFP for PIP3, CKAR for PKC activity, MARCKSp-mRFP for MARCKS membrane binding, leading-edge area), pharmacological inhibitors (wortmannin, EGTA, Go6976), PDGF and ATP stimulation","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — four orthogonal live-cell biosensors in macrophages with activators and inhibitors testing distinct pathway nodes; consistent with the in vitro reconstitution data from the same group","pmids":["29715315"],"is_preprint":false},{"year":2014,"finding":"Phosphorylated MARCKS (pMARCKS) functions as an E2F-1 cofactor to regulate SKP2 transcription, thereby facilitating cell-cycle progression by suppressing p27Kip1 and promoting Cyclin E/CDK2 activity in multiple myeloma.","method":"iTRAQ mass spectrometry, RNAi knockdown, pharmacological inhibition (enzastaurin), co-factor/transcription assay, cell-cycle analysis, xenograft model","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological manipulation with defined molecular mechanism (E2F-1 co-factor); single laboratory","pmids":["25179733"],"is_preprint":false},{"year":2019,"finding":"MARCKS is acetylated by the acetyltransferase Tip60 at lysine 165 under high glucose conditions, and this acetylation is a prerequisite for subsequent PKC-mediated phosphorylation; SIRT2 deacetylates MARCKS and reverses this modification; phosphorylated/translocated MARCKS leads to mitochondrial abnormalities and ER stress.","method":"Co-IP, acetyltransferase assay with Tip60, SIRT2 deacetylation assay, phosphorylation-dead MARCKS (PD-MARCKS) expression, SIRT2 rescue in neuroepithelium, organelle stress assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — identified writer (Tip60) and eraser (SIRT2) for MARCKS acetylation with functional consequence established via phosphorylation-dead mutant and genetic rescue; multiple orthogonal methods","pmids":["30655546"],"is_preprint":false},{"year":2017,"finding":"ENaC activity is regulated by calpain-2 proteolysis of MARCKS; calpain-2 cleaves MARCKS (but not ENaC subunits) in a Ca2+-dependent manner; calpain-2 inhibition reduces the association between ENaC and MARCKS and decreases ENaC open probability.","method":"In vitro calpain-2 cleavage assay with recombinant fusion proteins, pharmacological calpain-2 inhibition, single-channel patch-clamp, transepithelial current, sucrose gradient fractionation, co-immunoprecipitation","journal":"American journal of physiology. Cell physiology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct enzyme substrate reconstitution (recombinant proteins + Ca2+), complemented by pharmacological inhibition and electrophysiological readouts; multiple orthogonal methods","pmids":["28468944"],"is_preprint":false},{"year":2000,"finding":"Platelet secretion (serotonin release) induced by phorbol esters requires MARCKS phosphorylation; a peptide corresponding to the MARCKS phosphorylation site domain (MPSD) blocks MARCKS phosphorylation and serotonin secretion in permeabilized platelets without affecting pleckstrin or myosin light chain phosphorylation.","method":"Permeabilized platelet secretion assay, MARCKS phosphorylation assay, specific phosphorylation site domain peptide (MPSD) vs. alanine-substituted control peptide, time-course analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific phosphorylation site peptide with control (Ala-MPSD) plus parallel time-course and specificity controls; single laboratory","pmids":["10648401"],"is_preprint":false},{"year":2002,"finding":"PKCβ-MARCKS signaling is required for angiotensin II-stimulated vesicular trafficking along neurites in neurons; antisense knockdown of PKCβ or MARCKS blocks translocation of dopamine-β-hydroxylase-GFP-labeled vesicles from cell body to neurites.","method":"Real-time confocal microscopy of GFP-tagged vesicles, antisense oligonucleotides to PKCβ and MARCKS, PKC activators (PMA, carbachol, angiotensin II)","journal":"Hypertension","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live-cell imaging with antisense knockdown of two pathway components; single laboratory","pmids":["11882609"],"is_preprint":false},{"year":2002,"finding":"Protein phosphatase-1 (PP1)-mediated dephosphorylation of MARCKS promotes its translocation to the plasma membrane during myoblast fusion; phosphorylation-preventing MARCKS mutation promotes fusion, while myristoylation-deficient MARCKS (which cannot reach the membrane) impairs myoblast fusion.","method":"Okadaic acid and tautomycin (PP inhibitors), PP1 identification by dephosphorylation assay, MARCKS phosphorylation mutants (non-phosphorylatable and myristoylation-deficient), cell fusion assay","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic dissection of PP1 role with defined MARCKS mutants; single laboratory","pmids":["12045217"],"is_preprint":false},{"year":2006,"finding":"PKCε specifically phosphorylates MARCKS in cardiomyocytes; constitutively active PKCε increases phospho-MARCKS, dominant-negative PKCε reduces it and prevents co-localization of pMARCKS with F-actin; overexpression of wild-type MARCKS increases FAK phosphorylation and cardiomyocyte spreading, while non-phosphorylatable MARCKS blocks these effects.","method":"Adenoviral overexpression of wild-type, constitutively active, dominant-negative PKCε/δ/α, and GFP-tagged MARCKS mutants in neonatal and adult rat ventricular myocytes; immunofluorescence; FAK phosphorylation assay; cell area measurement","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific PKC dissection with multiple MARCKS mutants and functional readouts; single laboratory","pmids":["17157309"],"is_preprint":false},{"year":2012,"finding":"PP2A interacts with MARCKS and is the dominant phosphatase for MARCKS after bradykinin-induced transient phosphorylation; this transient MARCKS phosphorylation (via PKC-RhoA/ROCK cascade) is required for bradykinin-induced neurite outgrowth.","method":"PP2A inhibitors (calyculin A, fostriecin), co-immunoprecipitation of PP2A with MARCKS, GST pull-down, SH-SY5Y cells expressing wild-type and unphosphorylatable MARCKS, cell morphology analysis","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and phosphatase inhibitors plus MARCKS phosphorylation mutant with defined morphological readout; single laboratory","pmids":["21448919"],"is_preprint":false},{"year":2021,"finding":"Phosphorylated MARCKS (at Ser159/163) directly binds to NF-κB-activating protein (NKAP); upon MARCKS phosphorylation, the MARCKS-NKAP interaction is inhibited, releasing NKAP and leading to NF-κB activation in lung cancer cells.","method":"Functional proteomics (MARCKS interactome), co-immunoprecipitation, genetic knockdown, MPS peptide (phosphorylation inhibitor), phosphorylation site analysis (Ser159/163), cytokine measurement","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP interactome plus genetic and pharmacological validation; single laboratory","pmids":["33754052"],"is_preprint":false},{"year":2015,"finding":"MARCKS knockdown in VSMCs arrests cell cycle at G0/G1 via p27kip1 nuclear trapping through decreased KIS expression; this is p27kip1-dependent (confirmed in p27kip1-/- mice) and rescued by KIS overexpression; in endothelial cells, MARCKS knockdown paradoxically increases KIS and proliferation.","method":"siRNA knockdown in VSMCs and ECs, p27kip1-/- mouse-derived VSMCs, adenoviral KIS overexpression, cell cycle analysis, p27kip1 phosphorylation and localization assays, murine aortic injury model with BrdU","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic rescue (KIS overexpression) plus null cell validation in two cell types with in vivo confirmation; single laboratory","pmids":["26528715"],"is_preprint":false},{"year":2018,"finding":"Membrane-tethered MARCKS suppresses BCR nanoclustering and tonic/chronic active BCR signaling by disturbing the interaction between cortical F-actin and the inner leaflet of the plasma membrane, thereby increasing BCR lateral mobility; genetically induced MARCKS loss increases AKT signaling and B-cell migratory capacity.","method":"Single-molecule tracking in live cells, MARCKS mutants (membrane-tethered and membrane-untethered), MARCKS knockout, BCR nanoclustering analysis, AKT phosphorylation assay, migration assay","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single-molecule tracking with defined MARCKS mutants and KO; multiple functional readouts; single laboratory","pmids":["30209404"],"is_preprint":false},{"year":2009,"finding":"MCP-1-induced macrophage migration involves rapid MARCKS phosphorylation and translocation from plasma membrane to cytosol, accompanied by actin redistribution into cell protrusions; transient MARCKS-actin interaction during migration was detected biochemically.","method":"MANS peptide inhibition, confocal microscopy with fluorescent anti-MARCKS antibody and phalloidin, MARCKS phosphorylation/translocation assay, J774A.1 and primary mouse macrophage migration assay","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific peptide inhibitor and confocal imaging with biochemical co-localization; single laboratory","pmids":["22623357"],"is_preprint":false},{"year":2024,"finding":"TRIM1-269aa (encoded by circTRIM1) enhances the interaction between MARCKS and calmodulin, thereby promoting calmodulin-dependent translocation of MARCKS from the membrane, which further activates the PI3K/AKT/mTOR pathway in TNBC cells.","method":"Co-immunoprecipitation of MARCKS-calmodulin complex with/without TRIM1-269aa, MARCKS translocation assay, PI3K/AKT/mTOR pathway readout","journal":"Molecular cancer","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP in cell lines; mechanistic claim about MARCKS regulation supported only by co-IP with limited validation of the MARCKS-specific step","pmids":["38755678"],"is_preprint":false},{"year":2020,"finding":"WNT5A-induced PKC activation leads to increased MARCKS expression and phosphorylation; MARCKS phosphorylation at the leading edge is required for WNT5A-mediated melanoma cell invasion, as demonstrated by siRNA-mediated MARCKS knockdown and a MARCKS phosphorylation inhibitor peptide.","method":"Recombinant WNT5A treatment, WNT5A siRNA, MARCKS siRNA, MARCKS phosphorylation inhibitor peptide, confocal imaging of pMARCKS at leading edge, invasion assay","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (siRNA) and pharmacological (phosphorylation inhibitor) approaches converge on same invasion phenotype; single laboratory","pmids":["32033033"],"is_preprint":false}],"current_model":"MARCKS is a myristoylated, intrinsically disordered PKC substrate that shuttles between the inner plasma membrane leaflet and cytosol via a 'myristoyl-electrostatic switch': in the unphosphorylated state, its basic effector domain electrostatically anchors it to acidic phospholipids (especially PIP2), where it crosslinks F-actin, sequesters PIP2 (thereby inhibiting PI3K/PIP3 production), binds calmodulin, and stabilizes cortical cytoskeletal structures; upon phosphorylation at Ser152/156/163 by PKC (with δ- and ε-isoforms being cell-type-specific writers), the effector domain's affinity for membranes and calmodulin falls ~200-fold, releasing sequestered PIP2 to feed the PI3K–PIP3 amplification module at the leading edge, allowing calmodulin-dependent enzymes to activate, and routing MARCKS to lysosomes (via cathepsin B cleavage) or to the cytosol; Tip60 acetylation at K165 is a prerequisite for phosphorylation, reversed by SIRT2, while PP1 and PP2A dephosphorylate MARCKS to return it to the membrane; these reversible modifications collectively regulate F-actin dynamics, cell spreading, migration, vesicular trafficking, mucin secretion, ENaC activity, BCR signaling, and brain development."},"narrative":{"mechanistic_narrative":"MARCKS is a myristoylated, calmodulin- and phospholipid-binding protein that couples the cortical actin cytoskeleton to the inner leaflet of the plasma membrane and acts as a reversible, PKC-controlled relay in motility, secretion, and signaling [PMID:1560845, PMID:9259558, PMID:15316066]. It crosslinks F-actin and tethers to acidic phospholipids through two cooperating modules—an N-terminal myristoyl moiety and a basic effector domain—and both actin crosslinking and membrane binding are switched off by PKC phosphorylation of the effector domain and by Ca2+-calmodulin binding [PMID:1560845, PMID:8486722, PMID:2002042, PMID:9804991]. This 'myristoyl-electrostatic switch' drives bi-directional cycling between membrane and cytosol: phosphorylation (followed by PP1/PP2A dephosphorylation) governs translocation, lysosomal targeting via cathepsin B cleavage, and the membrane-versus-cytosol balance required for cell spreading, adhesion, and stress-fiber maturation [PMID:7720702, PMID:9295331, PMID:8262213, PMID:15316066, PMID:12045217]. At the membrane MARCKS sequesters PIP2 and restrains PI3K, so PKC-driven release of PIP2 recruits and activates PI3K to form a leading-edge Ca2+–PKC–MARCKS–PIP2–PI3K amplification module that controls PIP3 signaling and directed migration [PMID:27119641, PMID:29715315]. Through this switch MARCKS regulates diverse processes including airway mucin secretion via PKCδ, neutrophil and macrophage migration, megakaryocyte proplatelet formation, and ENaC channel activity through PIP2 availability [PMID:18055557, PMID:19574534, PMID:22791334, PMID:25515270, PMID:26744461, PMID:22623357]. MARCKS is also acetylated at Lys165 by Tip60 as a prerequisite for phosphorylation and deacetylated by SIRT2, and it binds LPS through an effector-domain heptapeptide to dampen TLR4 signaling [PMID:22427633, PMID:30655546]. MARCKS is required for normal brain development, where membrane association mediated by its myristoylation domain governs radial glial progenitor placement [PMID:7862670, PMID:19666823].","teleology":[{"year":1991,"claim":"Established that PKC phosphorylation of the effector domain is a molecular switch controlling calmodulin affinity, explaining how MARCKS could gate calmodulin-dependent enzyme activation.","evidence":"Synthetic effector-domain peptide phosphorylated by PKC in vitro with calmodulin binding and CaM-enzyme activity assays","pmids":["2002042"],"confidence":"High","gaps":["Done with a 25-mer peptide, not full-length protein in cells","Numbering (Ser8/Ser12) of the peptide not yet mapped to physiological residues"]},{"year":1992,"claim":"Identified MARCKS as a regulated F-actin crosslinker, linking it physically to the cortical cytoskeleton and showing both PKC and calmodulin inhibit this activity.","evidence":"In vitro F-actin crosslinking assay with PKC phosphorylation and calmodulin binding","pmids":["1560845"],"confidence":"High","gaps":["Crosslinking shown in vitro; cellular consequences not yet established","No structural model of the actin-binding interface"]},{"year":1993,"claim":"Defined the bipartite membrane-anchoring mechanism (myristoyl plus basic domain) and showed phosphorylation lowers phospholipid affinity, giving a physical basis for membrane release.","evidence":"Purified MARCKS and effector peptide binding to defined liposomes with PKC phosphorylation; mapping of PKC sites to Ser152/156/163 by tryptic analysis","pmids":["8486722","8422248"],"confidence":"High","gaps":["Phospho-site mapping from a single laboratory","Lipid binding measured on planar/vesicle systems, not native membranes"]},{"year":1993,"claim":"Identified PP1/PP2A as the phosphatases that reverse PKC phosphorylation, completing the reversible cycle that returns MARCKS to the membrane.","evidence":"Cell-free phosphatase assays and okadaic acid treatment in Swiss 3T3 cells","pmids":["8262213"],"confidence":"Medium","gaps":["Specific phosphatase responsible in vivo not resolved among PP1/PP2A/PP2C","No demonstration of physiological membrane re-targeting at this stage"]},{"year":1995,"claim":"Demonstrated that phosphorylation is required for MARCKS translocation and lysosomal targeting in cells, and that MARCKS is essential for brain development.","evidence":"Phosphorylation-deficient mutants with immuno-EM/fractionation in fibroblasts; knockout mice with developmental phenotyping","pmids":["7720702","7862670"],"confidence":"High","gaps":["Cellular targets mediating the developmental phenotype not yet defined","Route to lysosomes mechanistically incomplete"]},{"year":1997,"claim":"Identified cathepsin B as the MARCKS-cleaving enzyme and showed the myristoyl-electrostatic switch is required for cell spreading and adhesion.","evidence":"Cathepsin B co-purification and cell-free cleavage with CA074-Me; switch-mutant expression in fibroblasts with morphology and adhesion assays","pmids":["9295331","9259558"],"confidence":"High","gaps":["Functional role of the p40 cleavage product unknown","Switch-mutant phenotype from single laboratory"]},{"year":2003,"claim":"Refined the calmodulin interaction by showing the myristoyl group itself contributes phosphorylation-independent, ionic-strength-independent calmodulin binding.","evidence":"Calmodulin-agarose chromatography and dansyl-calmodulin assays with myristoylated vs non-myristoylated MARCKS and N-terminal peptides","pmids":["14506265"],"confidence":"High","gaps":["Physiological relevance of N-terminal CaM binding versus effector-domain binding unresolved"]},{"year":2009,"claim":"Separated MARCKS's developmental functions by domain, showing membrane association via myristoylation (not phosphorylation) drives radial glial progenitor placement.","evidence":"Knockout mice rescued with phosphorylation-deficient and myristoylation-deficient mutants","pmids":["19666823"],"confidence":"High","gaps":["Downstream effectors in radial glia not identified"]},{"year":2012,"claim":"Defined MARCKS as a PIP2-sequestering regulator of ion channels and a lipid/curvature sensor, and as an LPS-binding modulator of TLR4 signaling.","evidence":"FRET/patch-clamp on ENaC; curvature-defined vesicle binding; NMR of the LPS-binding heptapeptide with KO MEFs","pmids":["22791334","23075500","22427633"],"confidence":"Medium","gaps":["ENaC and lipid-sensing data each from single laboratories","Whether LPS binding occurs at physiological concentrations in vivo unresolved"]},{"year":2016,"claim":"Reconstituted the PKC–MARCKS–PIP2–PI3K leading-edge amplification module at single-molecule resolution and confirmed it as a positive-feedback loop in live macrophages.","evidence":"Single-molecule fluorescence on lipid bilayers; live-cell biosensors with activators/inhibitors in macrophages","pmids":["27119641","29715315"],"confidence":"High","gaps":["Quantitative contribution relative to other PIP2 effectors in vivo not established"]},{"year":2019,"claim":"Identified an acetylation layer upstream of phosphorylation, with Tip60 acetylating Lys165 as a prerequisite for PKC phosphorylation and SIRT2 reversing it.","evidence":"Tip60 acetyltransferase and SIRT2 deacetylation assays with phosphorylation-dead mutant and genetic rescue","pmids":["30655546"],"confidence":"High","gaps":["Generality of acetylation control beyond high-glucose neuroepithelium not established"]},{"year":2024,"claim":"Extended the calmodulin-translocation axis to disease, implicating a circRNA-encoded peptide in enhancing MARCKS-calmodulin binding and PI3K/AKT/mTOR activation.","evidence":"Co-IP of MARCKS-calmodulin with/without TRIM1-269aa and pathway readouts in TNBC cells","pmids":["38755678"],"confidence":"Low","gaps":["Single Co-IP with limited validation of the MARCKS-specific step","Direct effect on MARCKS translocation not biochemically isolated"]},{"year":null,"claim":"How the membrane/cytosol cycle, acetylation-priming, calmodulin extraction, and protease cleavage are integrated and spatially coordinated to produce tissue-specific outputs remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No integrated structural model of full-length MARCKS at membranes","Relative in vivo contributions of cathepsin B and calpain-2 cleavage unknown","Cause of opposite migration/proliferation outcomes across cell types unexplained"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[0,11]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[1,15,22]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,22,17]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,35]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,4,24]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[4,16,36]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[4,7]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[18]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[0,31]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[22,24,16]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[5,14]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[18,35]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[4,19,29]}],"complexes":[],"partners":["CALM1","PRKCD","PRKCE","PI3K","CTSB","CAPN2","NKAP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P29966","full_name":"Myristoylated alanine-rich C-kinase substrate","aliases":["Protein kinase C substrate, 80 kDa protein, light chain","80K-L protein","PKCSL"],"length_aa":332,"mass_kda":31.6,"function":"Membrane-associated protein that plays a role in the structural modulation of the actin cytoskeleton, chemotaxis, motility, cell adhesion, phagocytosis, and exocytosis through lipid sequestering and/or protein docking to membranes (PubMed:23704996, PubMed:36009319). Thus, exerts an influence on a plethora of physiological processes, such as embryonic development, tissue regeneration, neuronal plasticity, and inflammation. Sequesters phosphatidylinositol 4,5-bisphosphate (PIP2) at lipid rafts in the plasma membrane of quiescent cells, an action reversed by protein kinase C, ultimately inhibiting exocytosis (PubMed:23704996). During inflammation, promotes the migration and adhesion of inflammatory cells and the secretion of cytokines such as tumor necrosis factor (TNF), particularly in macrophages (PubMed:37949888). Plays an essential role in bacteria-induced intracellular reactive oxygen species (ROS) formation in the monocytic cell type. Participates in the regulation of neurite initiation and outgrowth by interacting with components of cellular machinery including CDC42 that regulates cell shape and process extension through modulation of the cytoskeleton (By similarity). Plays also a role in axon development by mediating docking and fusion of RAB10-positive vesicles with the plasma membrane (By similarity)","subcellular_location":"Cell membrane; Cytoplasm, cytoskeleton; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P29966/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MARCKS","classification":"Not Classified","n_dependent_lines":30,"n_total_lines":1208,"dependency_fraction":0.024834437086092714},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MARCKS","total_profiled":1310},"omim":[{"mim_id":"615559","title":"AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE III; ALPS3","url":"https://www.omim.org/entry/615559"},{"mim_id":"608353","title":"ANTIZYME INHIBITOR 2; AZIN2","url":"https://www.omim.org/entry/608353"},{"mim_id":"605940","title":"BRAIN-ABUNDANT SIGNAL PROTEIN, MEMBRANE-ATTACHED, 1; BASP1","url":"https://www.omim.org/entry/605940"},{"mim_id":"604072","title":"DIACYLGLYCEROL KINASE, IOTA, 130-KD; DGKI","url":"https://www.omim.org/entry/604072"},{"mim_id":"602940","title":"MARCKS-LIKE PROTEIN 1; MARCKSL1","url":"https://www.omim.org/entry/602940"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MARCKS"},"hgnc":{"alias_symbol":["PKCSL","80K-L"],"prev_symbol":["MACS"]},"alphafold":{"accession":"P29966","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29966","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29966-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29966-F1-predicted_aligned_error_v6.png","plddt_mean":49.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MARCKS","jax_strain_url":"https://www.jax.org/strain/search?query=MARCKS"},"sequence":{"accession":"P29966","fasta_url":"https://rest.uniprot.org/uniprotkb/P29966.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29966/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29966"}},"corpus_meta":[{"pmid":"1690625","id":"PMC_1690625","title":"High gradient magnetic cell separation with MACS.","date":"1990","source":"Cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/1690625","citation_count":1268,"is_preprint":false},{"pmid":"1560845","id":"PMC_1560845","title":"MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin.","date":"1992","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1560845","citation_count":683,"is_preprint":false},{"pmid":"19302977","id":"PMC_19302977","title":"MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19302977","citation_count":304,"is_preprint":false},{"pmid":"7862670","id":"PMC_7862670","title":"MARCKS deficiency in mice leads to abnormal brain development and perinatal death.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7862670","citation_count":272,"is_preprint":false},{"pmid":"11829734","id":"PMC_11829734","title":"Cross-talk unfolded: MARCKS proteins.","date":"2002","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11829734","citation_count":270,"is_preprint":false},{"pmid":"1455513","id":"PMC_1455513","title":"Signal transduction and the actin cytoskeleton: the roles of MARCKS and profilin.","date":"1992","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/1455513","citation_count":198,"is_preprint":false},{"pmid":"8486722","id":"PMC_8486722","title":"Interaction of myristoylated alanine-rich protein kinase C substrate (MARCKS) with membrane phospholipids.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8486722","citation_count":143,"is_preprint":false},{"pmid":"9259558","id":"PMC_9259558","title":"MARCKS regulates membrane ruffling and cell spreading.","date":"1997","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/9259558","citation_count":142,"is_preprint":false},{"pmid":"2002042","id":"PMC_2002042","title":"Phosphorylation-dependent binding of a synthetic MARCKS peptide to calmodulin.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2002042","citation_count":131,"is_preprint":false},{"pmid":"1516135","id":"PMC_1516135","title":"MacMARCKS, a novel member of the MARCKS family of protein kinase C substrates.","date":"1992","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1516135","citation_count":117,"is_preprint":false},{"pmid":"7720702","id":"PMC_7720702","title":"Protein kinase C regulates MARCKS cycling between the plasma membrane and lysosomes in fibroblasts.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/7720702","citation_count":112,"is_preprint":false},{"pmid":"29788979","id":"PMC_29788979","title":"MARCKS and MARCKS-like proteins in development and regeneration.","date":"2018","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/29788979","citation_count":106,"is_preprint":false},{"pmid":"1688057","id":"PMC_1688057","title":"The role of protein kinase C and its neuronal substrates dephosphin, B-50, and MARCKS in neurotransmitter release.","date":"1991","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/1688057","citation_count":106,"is_preprint":false},{"pmid":"16125549","id":"PMC_16125549","title":"Nerve ending \"signal\" proteins GAP-43, MARCKS, and BASP1.","date":"2005","source":"International review of cytology","url":"https://pubmed.ncbi.nlm.nih.gov/16125549","citation_count":99,"is_preprint":false},{"pmid":"9804991","id":"PMC_9804991","title":"MARCKS, membranes, and calmodulin: kinetics of their interaction.","date":"1998","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9804991","citation_count":99,"is_preprint":false},{"pmid":"7765076","id":"PMC_7765076","title":"YACs, BACs, PACs and MACs: artificial chromosomes as research tools.","date":"1994","source":"Trends in biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/7765076","citation_count":98,"is_preprint":false},{"pmid":"1860846","id":"PMC_1860846","title":"The human myristoylated alanine-rich C kinase substrate (MARCKS) gene (MACS). Analysis of its gene product, promoter, and chromosomal localization.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1860846","citation_count":89,"is_preprint":false},{"pmid":"23468098","id":"PMC_23468098","title":"Sperm selection using magnetic activated cell sorting (MACS) in assisted reproduction: a systematic review and meta-analysis.","date":"2013","source":"Journal of assisted reproduction and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23468098","citation_count":85,"is_preprint":false},{"pmid":"15052337","id":"PMC_15052337","title":"The MARCKS family of phospholipid binding proteins: regulation of phospholipase D and other cellular components.","date":"2004","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/15052337","citation_count":79,"is_preprint":false},{"pmid":"9344590","id":"PMC_9344590","title":"The motility-associated proteins GAP-43, MARCKS, and CAP-23 share unique targeting and surface activity-inducing properties.","date":"1997","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/9344590","citation_count":76,"is_preprint":false},{"pmid":"32810482","id":"PMC_32810482","title":"Methodological comparison of FACS and MACS isolation of enriched microglia and astrocytes from mouse brain.","date":"2020","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/32810482","citation_count":72,"is_preprint":false},{"pmid":"27863012","id":"PMC_27863012","title":"Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity.","date":"2016","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/27863012","citation_count":71,"is_preprint":false},{"pmid":"19666823","id":"PMC_19666823","title":"MARCKS modulates radial progenitor placement, proliferation and organization in the developing cerebral cortex.","date":"2009","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19666823","citation_count":68,"is_preprint":false},{"pmid":"27119641","id":"PMC_27119641","title":"Regulation of PI3K by PKC and MARCKS: Single-Molecule Analysis of a Reconstituted Signaling Pathway.","date":"2016","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/27119641","citation_count":64,"is_preprint":false},{"pmid":"25257881","id":"PMC_25257881","title":"Isolation and characterisation of human gingival margin-derived STRO-1/MACS(+) and MACS(-) cell populations.","date":"2015","source":"International journal of oral science","url":"https://pubmed.ncbi.nlm.nih.gov/25257881","citation_count":63,"is_preprint":false},{"pmid":"25179733","id":"PMC_25179733","title":"Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.","date":"2014","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/25179733","citation_count":63,"is_preprint":false},{"pmid":"19574534","id":"PMC_19574534","title":"Myristoylated alanine-rich C-kinase substrate (MARCKS) protein regulation of human neutrophil migration.","date":"2009","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19574534","citation_count":62,"is_preprint":false},{"pmid":"8422248","id":"PMC_8422248","title":"Protein kinase C phosphorylates Ser152, Ser156 and Ser163 but not Ser160 of MARCKS in rat brain.","date":"1993","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8422248","citation_count":60,"is_preprint":false},{"pmid":"10648401","id":"PMC_10648401","title":"Platelet secretion induced by phorbol esters stimulation is mediated through phosphorylation of MARCKS: a MARCKS-derived peptide blocks MARCKS phosphorylation and serotonin release without affecting pleckstrin phosphorylation.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10648401","citation_count":59,"is_preprint":false},{"pmid":"23075500","id":"PMC_23075500","title":"MARCKS-ED peptide as a curvature and lipid sensor.","date":"2012","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/23075500","citation_count":59,"is_preprint":false},{"pmid":"22791334","id":"PMC_22791334","title":"Phosphatidylinositol phosphate-dependent regulation of Xenopus ENaC by MARCKS protein.","date":"2012","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22791334","citation_count":57,"is_preprint":false},{"pmid":"29039083","id":"PMC_29039083","title":"Myristoylated alanine-rich C kinase substrate (MARCKS): a multirole signaling protein in cancers.","date":"2017","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29039083","citation_count":52,"is_preprint":false},{"pmid":"34509657","id":"PMC_34509657","title":"The myristoylated alanine-rich C-kinase substrates (MARCKS): A membrane-anchored mediator of the cell function.","date":"2021","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/34509657","citation_count":49,"is_preprint":false},{"pmid":"26528135","id":"PMC_26528135","title":"X MARCKS the spot: myristoylated alanine-rich C kinase substrate in neuronal function and disease.","date":"2015","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26528135","citation_count":49,"is_preprint":false},{"pmid":"15316066","id":"PMC_15316066","title":"The bi-directional translocation of MARCKS between membrane and cytosol regulates integrin-mediated muscle cell spreading.","date":"2004","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15316066","citation_count":49,"is_preprint":false},{"pmid":"26136560","id":"PMC_26136560","title":"Calmodulin and CaMKII modulate ENaC activity by regulating the association of MARCKS and the cytoskeleton with the apical membrane.","date":"2015","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26136560","citation_count":49,"is_preprint":false},{"pmid":"1370466","id":"PMC_1370466","title":"MARCKS protein is transcriptionally down-regulated in v-Src-transformed BALB/c 3T3 cells.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1370466","citation_count":47,"is_preprint":false},{"pmid":"18055557","id":"PMC_18055557","title":"Protein kinase C delta regulates airway mucin secretion via phosphorylation of MARCKS protein.","date":"2007","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18055557","citation_count":45,"is_preprint":false},{"pmid":"9674561","id":"PMC_9674561","title":"Distribution of the protein kinase C substrates MARCKS and MRP in the postnatal developing rat brain.","date":"1998","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/9674561","citation_count":45,"is_preprint":false},{"pmid":"28166200","id":"PMC_28166200","title":"Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28166200","citation_count":42,"is_preprint":false},{"pmid":"25547726","id":"PMC_25547726","title":"Eliminating the heart from the curcumin molecule: monocarbonyl curcumin mimics (MACs).","date":"2014","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/25547726","citation_count":42,"is_preprint":false},{"pmid":"22623357","id":"PMC_22623357","title":"Directed migration of mouse macrophages in vitro involves myristoylated alanine-rich C-kinase substrate (MARCKS) protein.","date":"2012","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/22623357","citation_count":40,"is_preprint":false},{"pmid":"14506265","id":"PMC_14506265","title":"Direct involvement of protein myristoylation in myristoylated alanine-rich C kinase substrate (MARCKS)-calmodulin interaction.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14506265","citation_count":40,"is_preprint":false},{"pmid":"38755678","id":"PMC_38755678","title":"CircTRIM1 encodes TRIM1-269aa to promote chemoresistance and metastasis of TNBC via enhancing CaM-dependent MARCKS translocation and PI3K/AKT/mTOR activation.","date":"2024","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38755678","citation_count":39,"is_preprint":false},{"pmid":"10736562","id":"PMC_10736562","title":"MARCKS: a case of molecular exaptation?","date":"2000","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10736562","citation_count":39,"is_preprint":false},{"pmid":"8262213","id":"PMC_8262213","title":"Okadaic acid-sensitive protein phosphatases dephosphorylate MARCKS, a major protein kinase C substrate.","date":"1993","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8262213","citation_count":39,"is_preprint":false},{"pmid":"26744461","id":"PMC_26744461","title":"Synthesis and dephosphorylation of MARCKS in the late stages of megakaryocyte maturation drive proplatelet formation.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26744461","citation_count":39,"is_preprint":false},{"pmid":"24662837","id":"PMC_24662837","title":"Functional characterization of the tumor-suppressor MARCKS in colorectal cancer and its association with survival.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24662837","citation_count":39,"is_preprint":false},{"pmid":"21281703","id":"PMC_21281703","title":"Regulation of mucin secretion and inflammation in asthma: a role for MARCKS protein?","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21281703","citation_count":38,"is_preprint":false},{"pmid":"33754052","id":"PMC_33754052","title":"MARCKS cooperates with NKAP to activate NF-kB signaling in smoke-related lung cancer.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/33754052","citation_count":36,"is_preprint":false},{"pmid":"8922669","id":"PMC_8922669","title":"Developmental expression of MARCKS and protein kinase C in mice in relation to the exencephaly resulting from MARCKS deficiency.","date":"1996","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/8922669","citation_count":36,"is_preprint":false},{"pmid":"26015406","id":"PMC_26015406","title":"Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26015406","citation_count":35,"is_preprint":false},{"pmid":"25929183","id":"PMC_25929183","title":"Myristoylated alanine-rich C kinase substrate (MARCKS) regulates the expression of proinflammatory cytokines in macrophages through activation of p38/JNK MAPK and NF-κB.","date":"2015","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25929183","citation_count":35,"is_preprint":false},{"pmid":"30655546","id":"PMC_30655546","title":"Tip60- and sirtuin 2-regulated MARCKS acetylation and phosphorylation are required for diabetic embryopathy.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30655546","citation_count":34,"is_preprint":false},{"pmid":"10409119","id":"PMC_10409119","title":"Phagocytic and macropinocytic activity in MARCKS-deficient macrophages and fibroblasts.","date":"1999","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10409119","citation_count":34,"is_preprint":false},{"pmid":"22927426","id":"PMC_22927426","title":"MARCKS protein mediates hydrogen peroxide regulation of endothelial permeability.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22927426","citation_count":34,"is_preprint":false},{"pmid":"9295331","id":"PMC_9295331","title":"Identification and characterization of cathepsin B as the cellular MARCKS cleaving enzyme.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9295331","citation_count":34,"is_preprint":false},{"pmid":"29715315","id":"PMC_29715315","title":"A PKC-MARCKS-PI3K regulatory module links Ca2+ and PIP3 signals at the leading edge of polarized macrophages.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29715315","citation_count":34,"is_preprint":false},{"pmid":"27081703","id":"PMC_27081703","title":"MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27081703","citation_count":33,"is_preprint":false},{"pmid":"19924305","id":"PMC_19924305","title":"A cell motility screen reveals role for MARCKS-related protein in adherens junction formation and tumorigenesis.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19924305","citation_count":33,"is_preprint":false},{"pmid":"25515270","id":"PMC_25515270","title":"In Vitro Neutrophil Migration Requires Protein Kinase C-Delta (δ-PKC)-Mediated Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) Phosphorylation.","date":"2015","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/25515270","citation_count":32,"is_preprint":false},{"pmid":"19509053","id":"PMC_19509053","title":"Dynamic adhesions and MARCKS in melanoma cells.","date":"2009","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/19509053","citation_count":31,"is_preprint":false},{"pmid":"9598313","id":"PMC_9598313","title":"Promoter sequence, expression, and fine chromosomal mapping of the human gene (MLP) encoding the MARCKS-like protein: identification of neighboring and linked polymorphic loci for MLP and MACS and use in the evaluation of human neural tube defects.","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9598313","citation_count":30,"is_preprint":false},{"pmid":"20205598","id":"PMC_20205598","title":"Inhibition of myristoylated alanine-rich C kinase substrate (MARCKS) protein inhibits ozone-induced airway neutrophilia and inflammation.","date":"2010","source":"Experimental lung research","url":"https://pubmed.ncbi.nlm.nih.gov/20205598","citation_count":30,"is_preprint":false},{"pmid":"28009981","id":"PMC_28009981","title":"MARCKS protein overexpression in inflammatory breast cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28009981","citation_count":29,"is_preprint":false},{"pmid":"32772268","id":"PMC_32772268","title":"PICSI vs. MACS for abnormal sperm DNA fragmentation ICSI cases: a prospective randomized trial.","date":"2020","source":"Journal of assisted reproduction and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32772268","citation_count":29,"is_preprint":false},{"pmid":"19421174","id":"PMC_19421174","title":"Enrichment of cell subpopulations applying automated MACS technique: purity, recovery and applicability for PCR-based chimerism analysis.","date":"2009","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/19421174","citation_count":29,"is_preprint":false},{"pmid":"30893384","id":"PMC_30893384","title":"Isolation of B-cells using Miltenyi MACS bead isolation kits.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30893384","citation_count":28,"is_preprint":false},{"pmid":"11029309","id":"PMC_11029309","title":"Role of MARCKS in regulating endothelial cell proliferation.","date":"2000","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11029309","citation_count":28,"is_preprint":false},{"pmid":"28468944","id":"PMC_28468944","title":"ENaC activity is regulated by calpain-2 proteolysis of MARCKS proteins.","date":"2017","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28468944","citation_count":28,"is_preprint":false},{"pmid":"26722462","id":"PMC_26722462","title":"miR-34c-3p inhibits cell proliferation, migration and invasion of hepatocellular carcinoma by targeting MARCKS.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26722462","citation_count":28,"is_preprint":false},{"pmid":"23424156","id":"PMC_23424156","title":"Taurolithocholate-induced MRP2 retrieval involves MARCKS phosphorylation by protein kinase Cϵ in HUH-NTCP Cells.","date":"2013","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23424156","citation_count":27,"is_preprint":false},{"pmid":"23840497","id":"PMC_23840497","title":"Fibroblast Migration Is Regulated by Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) Protein.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23840497","citation_count":27,"is_preprint":false},{"pmid":"10942213","id":"PMC_10942213","title":"Analogous structural motifs in myelin basic protein and in MARCKS.","date":"2000","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10942213","citation_count":27,"is_preprint":false},{"pmid":"25757715","id":"PMC_25757715","title":"Altered prefrontal cortical MARCKS and PPP1R9A mRNA expression in schizophrenia and bipolar disorder.","date":"2015","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/25757715","citation_count":26,"is_preprint":false},{"pmid":"1427822","id":"PMC_1427822","title":"Chromosomal mapping of the human (MACS) and mouse (Macs) genes encoding the MARCKS protein.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1427822","citation_count":26,"is_preprint":false},{"pmid":"28494265","id":"PMC_28494265","title":"Intramyocardial fate and effect of iron nanoparticles co-injected with MACS® purified stem cell products.","date":"2017","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/28494265","citation_count":25,"is_preprint":false},{"pmid":"28363994","id":"PMC_28363994","title":"Validating the Manchester Acute Coronary Syndromes (MACS) and Troponin-only Manchester Acute Coronary Syndromes (T-MACS) rules for the prediction of acute myocardial infarction in patients presenting to the emergency department with chest pain.","date":"2017","source":"Emergency medicine journal : EMJ","url":"https://pubmed.ncbi.nlm.nih.gov/28363994","citation_count":25,"is_preprint":false},{"pmid":"1396720","id":"PMC_1396720","title":"Relationship between the major protein kinase C substrates acidic 80-kDa protein-kinase-C substrate (80K) and myristoylated alanine-rich C-kinase substrate (MARCKS). Members of a gene family or equivalent genes in different species.","date":"1992","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1396720","citation_count":24,"is_preprint":false},{"pmid":"32033033","id":"PMC_32033033","title":"WNT5A-Induced Activation of the Protein Kinase C Substrate MARCKS Is Required for Melanoma Cell Invasion.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32033033","citation_count":24,"is_preprint":false},{"pmid":"7964753","id":"PMC_7964753","title":"Differential expression of MARCKS and other calmodulin-binding protein kinase C substrates in cultured neuroblastoma and glioma cells.","date":"1994","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7964753","citation_count":24,"is_preprint":false},{"pmid":"22773836","id":"PMC_22773836","title":"Angiotensin-II and MARCKS: a hydrogen peroxide- and RAC1-dependent signaling pathway in vascular endothelium.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22773836","citation_count":24,"is_preprint":false},{"pmid":"20543006","id":"PMC_20543006","title":"MARCKS-related peptide modulates in vivo the secretion of airway Muc5ac.","date":"2010","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20543006","citation_count":24,"is_preprint":false},{"pmid":"10757536","id":"PMC_10757536","title":"Phosphorylation of MARCKS in Alzheimer disease brains.","date":"2000","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/10757536","citation_count":24,"is_preprint":false},{"pmid":"30339463","id":"PMC_30339463","title":"MARCKS and Lung Disease.","date":"2019","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30339463","citation_count":23,"is_preprint":false},{"pmid":"29069765","id":"PMC_29069765","title":"MARCKS promotes invasion and is associated with biochemical recurrence in prostate cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29069765","citation_count":23,"is_preprint":false},{"pmid":"22427633","id":"PMC_22427633","title":"MARCKS as a negative regulator of lipopolysaccharide signaling.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22427633","citation_count":22,"is_preprint":false},{"pmid":"1798060","id":"PMC_1798060","title":"Phosphorylation of MARCKS (80-kDa) protein, a major substrate for protein kinase C in oligodendroglial progenitors.","date":"1991","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/1798060","citation_count":22,"is_preprint":false},{"pmid":"33735912","id":"PMC_33735912","title":"MARCKS affects cell motility and response to BTK inhibitors in CLL.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33735912","citation_count":21,"is_preprint":false},{"pmid":"36230850","id":"PMC_36230850","title":"The Role of MARCKS in Metastasis and Treatment Resistance of Solid Tumors.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36230850","citation_count":20,"is_preprint":false},{"pmid":"12045217","id":"PMC_12045217","title":"Involvement of protein phosphatase-1-mediated MARCKS translocation in myogenic differentiation of embryonic muscle cells.","date":"2002","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/12045217","citation_count":20,"is_preprint":false},{"pmid":"30209404","id":"PMC_30209404","title":"MARCKS regulates tonic and chronic active B cell receptor signaling.","date":"2018","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30209404","citation_count":19,"is_preprint":false},{"pmid":"31661644","id":"PMC_31661644","title":"Tackling MARCKS-PIP3 circuit attenuates fibroblast activation and fibrosis progression.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31661644","citation_count":19,"is_preprint":false},{"pmid":"11882609","id":"PMC_11882609","title":"Obligatory role of protein kinase Cbeta and MARCKS in vesicular trafficking in living neurons.","date":"2002","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/11882609","citation_count":19,"is_preprint":false},{"pmid":"17157309","id":"PMC_17157309","title":"Protein kinase Cepsilon-dependent MARCKS phosphorylation in neonatal and adult rat ventricular myocytes.","date":"2006","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/17157309","citation_count":18,"is_preprint":false},{"pmid":"20224071","id":"PMC_20224071","title":"Mesenchymal stem cells require MARCKS protein for directed chemotaxis in vitro.","date":"2010","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20224071","citation_count":18,"is_preprint":false},{"pmid":"21448919","id":"PMC_21448919","title":"MARCKS dephosphorylation is involved in bradykinin-induced neurite outgrowth in neuroblastoma SH-SY5Y cells.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21448919","citation_count":18,"is_preprint":false},{"pmid":"24857637","id":"PMC_24857637","title":"Myristoylated Alanine Rich C Kinase Substrate (MARCKS) is essential to β2-integrin dependent responses of equine neutrophils.","date":"2014","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/24857637","citation_count":18,"is_preprint":false},{"pmid":"27076218","id":"PMC_27076218","title":"Mammalian Synthetic Biology: Time for Big MACs.","date":"2016","source":"ACS synthetic biology","url":"https://pubmed.ncbi.nlm.nih.gov/27076218","citation_count":17,"is_preprint":false},{"pmid":"26528715","id":"PMC_26528715","title":"MARCKS Signaling Differentially Regulates Vascular Smooth Muscle and Endothelial Cell Proliferation through a KIS-, p27kip1- Dependent Mechanism.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26528715","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49793,"output_tokens":9736,"usd":0.147709,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20344,"output_tokens":4145,"usd":0.102672,"stage2_stop_reason":"end_turn"},"total_usd":0.250381,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"MARCKS is a filamentous (F)-actin crosslinking protein; this crosslinking activity is inhibited by PKC-mediated phosphorylation and by binding to calcium-calmodulin, establishing MARCKS as a regulated crossbridge between actin and the plasma membrane.\",\n      \"method\": \"In vitro F-actin crosslinking assay, PKC phosphorylation, calmodulin binding assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro reconstitution of actin crosslinking with defined enzymatic (PKC) and calmodulin inhibition; replicated conceptually across multiple subsequent studies\",\n      \"pmids\": [\"1560845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"MARCKS binds to phospholipid membranes through two sites: the N-terminal myristoyl moiety and the basic phosphorylation domain; phosphorylation of the basic domain by PKC lowers its affinity for negatively charged phospholipids (phosphatidylserine), causing dissociation from membranes.\",\n      \"method\": \"Purified MARCKS binding to liposomes (phosphatidylcholine and phosphatidylserine), synthetic phosphorylation domain peptide assays, PKC phosphorylation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro with purified protein and defined lipid vesicles; mutagenic dissection using synthetic peptide of phosphorylation domain\",\n      \"pmids\": [\"8486722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"PKC phosphorylation of the MARCKS effector domain peptide at Ser8 and Ser12 (with Ser12 being key) produces a ~200-fold decrease in calmodulin affinity, causing rapid release of bound calmodulin and enabling subsequent calmodulin-dependent enzyme activation.\",\n      \"method\": \"Synthetic MARCKS effector domain peptide (25-mer), PKC phosphorylation in vitro, calmodulin binding assay, calmodulin-dependent enzyme activity assays (phosphodiesterase, calcineurin, myosin light chain kinase)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — quantitative in vitro reconstitution with synthetic peptide, site-specific phosphorylation mapping, and functional calmodulin release assays\",\n      \"pmids\": [\"2002042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"In rat brain, PKC isoforms I, II, and III phosphorylate MARCKS at Ser152, Ser156, and Ser163, but not at Ser160 as previously reported; Ser152 and Ser156 are phosphorylated at twice the initial rate of Ser163, with no isoform preference.\",\n      \"method\": \"Tryptic peptide analysis of PKC-phosphorylated MARCKS and synthetic peptide, alpha-chymotrypsin digestion, 32P incorporation mapping\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous in vitro mapping with purified PKC isoforms and peptide analysis, but single laboratory, single method\",\n      \"pmids\": [\"8422248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"PKC-dependent phosphorylation regulates cycling of MARCKS between the plasma membrane and Lamp-1-positive lysosomes in fibroblasts; mutating PKC phosphorylation sites prevents both membrane release and lysosomal targeting, indicating phosphorylation is required for translocation.\",\n      \"method\": \"Immunofluorescence, immunoelectron microscopy, subcellular fractionation, PKC mutant MARCKS (phosphorylation-deficient), lysosomotropic agents, nocodazole\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (immunofluorescence, immuno-EM, fractionation) with defined phosphorylation-site mutants in intact cells\",\n      \"pmids\": [\"7720702\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"MARCKS is required for normal mouse brain development; MARCKS-deficient mice exhibit exencephaly, agenesis of corpus callosum, failure of cerebral hemisphere fusion, and cortical/retinal lamination abnormalities, with all pups dying perinatally.\",\n      \"method\": \"Homologous recombination gene disruption (knockout mice), histological analysis of embryos and pups\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined developmental phenotypes; replicated and extended in subsequent studies\",\n      \"pmids\": [\"7862670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Expression of a MARCKS mutant that abrogates the myristoyl-electrostatic switch prevents cell spreading in fibroblasts, arresting cells at an early stage with membrane blebbing and preventing membrane ruffle and lamellae formation, accompanied by decreased cell-substratum adhesion.\",\n      \"method\": \"Transfection of myristoyl-electrostatic switch mutant MARCKS in fibroblasts, cell morphology analysis, cell adhesion assay\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — structure-function mutant with defined cellular phenotype readouts; single laboratory, two orthogonal measurements (morphology + adhesion)\",\n      \"pmids\": [\"9259558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Cathepsin B is the cellular MARCKS-cleaving enzyme (MCE); it cleaves MARCKS at the lysosomal compartment to generate a carboxyl-terminal fragment (p40), and specific cathepsin B inhibitor CA074-Me blocks this cleavage in fibroblasts.\",\n      \"method\": \"Co-purification of MCE activity with cathepsin B immunoreactivity, cell-free cathepsin B cleavage assay, cell-permeable cathepsin B inhibitor (CA074-Me), subcellular fractionation, NH4Cl treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — enzyme identified by co-purification and cell-free reconstitution, confirmed with specific inhibitor in intact cells; single laboratory with multiple orthogonal methods\",\n      \"pmids\": [\"9295331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The kinetics of MARCKS effector domain peptide binding to phospholipid vesicles is diffusion-limited; Ca2+-calmodulin (5 µM) accelerates removal of the peptide from membranes by ~10-fold (reducing membrane lifetime from 0.1 s to 0.01 s), via a proposed diffusion-limited calmodulin extraction mechanism.\",\n      \"method\": \"Stopped-flow fluorescence measurements, spin-labeled EPR structure determination of membrane-bound effector peptide\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — quantitative kinetic measurements with reconstituted system, EPR structural validation, single laboratory with two orthogonal methods\",\n      \"pmids\": [\"9804991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Okadaic acid-sensitive phosphatases (PP1/PP2A) dephosphorylate MARCKS in intact Swiss 3T3 cells following PKC-mediated phosphorylation; PP1, PP2A, and PP2C can all dephosphorylate MARCKS in cell-free assays.\",\n      \"method\": \"Cell-free phosphatase assays with PP1, PP2A, PP2C; okadaic acid treatment in intact cells; bombesin-stimulated receptor blockade\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro enzyme assay plus cell-based pharmacological inhibition; single laboratory\",\n      \"pmids\": [\"8262213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The myristoyl moiety at the MARCKS N-terminus directly participates in calmodulin binding, providing ionic-strength-independent binding that is absent in non-myristoylated MARCKS; phosphorylation-independent calmodulin binding occurs through the N-terminal domain.\",\n      \"method\": \"Calmodulin-agarose chromatography with myristoylated vs. non-myristoylated recombinant MARCKS, quantitative dansyl-calmodulin binding assay, synthetic myristoylated N-terminal peptide, mutation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted binding with purified proteins, quantitative affinity measurements, mutagenesis, and synthetic peptide validation; single laboratory with multiple orthogonal methods\",\n      \"pmids\": [\"14506265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MARCKS bi-directional translocation between membrane and cytosol regulated by alpha5beta1 integrin-activated PKC is required for actin stress fiber formation during muscle cell spreading; PKC-dependent phosphorylation/membrane dissociation enables initial cell adhesion, while subsequent dephosphorylation/membrane return enables actin crosslinking and cytoskeletal maturation.\",\n      \"method\": \"MARCKS mutants (membrane association-deficient; PKC phosphorylation-deficient) in muscle cells, integrin-fibronectin binding assays, actin staining, cell spreading assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — structure-function mutants with defined phenotypes, integrin-specific pathway placement; single laboratory\",\n      \"pmids\": [\"15316066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PKC-delta (not PKC-epsilon) specifically phosphorylates MARCKS to regulate airway mucin secretion; dominant-negative PKC-delta blocks both MARCKS phosphorylation and mucin hypersecretion, while wild-type PKC-delta overexpression enhances both.\",\n      \"method\": \"Dominant-negative and wild-type PKC-delta/epsilon constructs transfected into bronchial epithelial cells, PKC-delta selective inhibitor rottlerin, MARCKS phosphorylation assay, mucin secretion assay\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative and wild-type constructs with parallel functional readouts; single laboratory, two orthogonal approaches (genetic + pharmacological)\",\n      \"pmids\": [\"18055557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MARCKS, via its myristoylated N-terminus, regulates human neutrophil migration and beta2 integrin-dependent adhesion; the MANS peptide (N-terminus mimic) reduces F-actin content after fMLF stimulation without affecting beta2 integrin surface expression.\",\n      \"method\": \"Cell-permeant MANS peptide treatment of human neutrophils, migration assays (fMLF, IL-8, LTB4), beta2 integrin expression by FACS, F-actin quantification\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific peptide inhibitor with multiple functional readouts; single laboratory\",\n      \"pmids\": [\"19574534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MARCKS modulates radial glial progenitor placement and proliferation in the developing cerebral cortex; the myristoylation domain (but not PKC phosphorylation sites) is essential for this function, suggesting membrane association is the key requirement for MARCKS role in radial glia.\",\n      \"method\": \"MARCKS knockout mice, genetic rescue with phosphorylation-deficient and myristoylation-deficient MARCKS mutants, immunostaining for polarity complexes and radial glia markers\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic rescue experiments with defined MARCKS mutants in vivo, dissecting phosphorylation vs. myristoylation requirements; clean KO phenotype with molecular pathway analysis\",\n      \"pmids\": [\"19666823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MARCKS is identified as a curvature and lipid sensor; the MARCKS effector domain (25-mer peptide) recognizes phosphatidylserine with preference for highly curved vesicles in a sequence-specific manner.\",\n      \"method\": \"Fluorescence-based lipid binding assays with vesicles of defined curvature and composition, sequence-specific peptide variants\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with defined lipid vesicles and systematic sequence variants; single laboratory\",\n      \"pmids\": [\"23075500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MARCKS mediates H2O2-induced endothelial permeability via a signaling cascade: Rac1 → Abl1 → PLCγ1 → PKCδ → MARCKS phosphorylation and translocation from membrane to cytosol, leading to actin cytoskeleton remodeling.\",\n      \"method\": \"siRNA knockdown of MARCKS and pathway components, pharmacological inhibitors, MARCKS phosphorylation/translocation assay, permeability assay in bovine aortic endothelial cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established by siRNA at multiple pathway nodes; single laboratory\",\n      \"pmids\": [\"22927426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MARCKS regulates Xenopus ENaC activity through PIP2-dependent mechanism; MARCKS sequesters PIP2 at the apical membrane, and its phosphorylation (PKC) or calmodulin-mediated dissociation from the membrane reduces PIP2 availability and ENaC open probability; FRET shows close proximity between ENaC and MARCKS when PKC activity is low.\",\n      \"method\": \"Lipid binding assay, co-immunoprecipitation, confocal microscopy, FRET, transepithelial current measurements, single-channel patch-clamp\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (co-IP, FRET, patch-clamp); single laboratory\",\n      \"pmids\": [\"22791334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MARCKS specifically binds LPS via a heptapeptide within its effector domain (determined by NMR); after LPS stimulation MARCKS translocates to FYVE-positive endosomes and co-localizes with LPS; MARCKS deficiency increases TLR4-specific (not TLR2/3/5) LPS signaling.\",\n      \"method\": \"NMR spectroscopy, LPS binding assay, confocal microscopy (FYVE endosome co-localization), MARCKS-deficient MEFs, siRNA knockdown, MARCKS overexpression, cytokine measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — NMR structure of binding interaction plus genetic (KO MEFs, siRNA, overexpression) functional data; single laboratory with multiple orthogonal methods\",\n      \"pmids\": [\"22427633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TLC-induced retrieval of MRP2 from the canalicular membrane in hepatocytes involves sequential PKCε activation → MARCKS phosphorylation → MARCKS detachment from membrane; phosphorylation-deficient MARCKS mutant blocks TLC-induced MRP2 retrieval.\",\n      \"method\": \"Dominant-negative PKCε transfection, phosphorylation-deficient MARCKS mutant transfection, subcellular fractionation (PM fractions), MARCKS phosphorylation assay in HuH-NTCP cells and rat hepatocytes\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (dominant-negative, phosphorylation-dead mutant) plus fractionation; single laboratory\",\n      \"pmids\": [\"23424156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"δ-PKC (not α-, β-, or ζ-PKC) is the specific isoform that phosphorylates MARCKS to regulate human neutrophil migration and adhesion in vitro; rottlerin (δ-PKC inhibitor) attenuates fMLF-induced MARCKS phosphorylation, adhesion, and migration.\",\n      \"method\": \"PKC isoform-selective inhibitors (rottlerin, Gö6976, others) on human neutrophils, MARCKS phosphorylation assay, migration and adhesion assays\",\n      \"journal\": \"Inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological isoform dissection with parallel functional readouts; single laboratory\",\n      \"pmids\": [\"25515270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Calmodulin binding to the MARCKS effector domain and CaMKII-mediated phosphorylation of filamin both promote dissociation of MARCKS from the apical membrane, reducing ENaC open probability; mutations in MARCKS preventing calmodulin association prevent membrane dissociation.\",\n      \"method\": \"Calmidazolium (calmodulin inhibitor), KN93 (CaMKII inhibitor), cytochalasin E (actin disruption), ENaC patch-clamp and transepithelial current, MARCKS calmodulin-binding mutants, co-immunoprecipitation\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple inhibitors and MARCKS mutants with defined electrophysiological readouts; single laboratory\",\n      \"pmids\": [\"26136560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Ca2+-PKC phosphorylation of MARCKS releases sequestered PIP2, which recruits and activates PI3K on the membrane surface; in the unphosphorylated state MARCKS sequesters PIP2 and inhibits PI3K membrane binding; this Ca2+-PKC-MARCKS-PIP2-PI3K module constitutes a leading-edge amplification circuit.\",\n      \"method\": \"Single-molecule fluorescence reconstitution on lipid bilayers, surface density measurements of PKC, MARCKS peptide, and PI3K; PKC phosphorylation assay\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted multi-protein signaling pathway on defined lipid bilayers with single-molecule resolution; quantitative mechanistic dissection in vitro, consistent with in vivo data\",\n      \"pmids\": [\"27119641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In megakaryocytes, dephosphorylated MARCKS promotes proplatelet formation; PKC-mediated MARCKS phosphorylation inhibits proplatelet formation and correlates with Arp2 phosphorylation; MARCKS KO mice show decreased proplatelet levels, and MARCKS inhibition reduces proplatelet formation by 53%.\",\n      \"method\": \"2D-DIGE proteomics, polysome profiling, MARCKS KO mice, PMA treatment, MARCKS peptide inhibition, Arp2 inhibitor assay, confocal localization\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO, peptide inhibition, and pharmacological manipulation with quantitative proplatelet readout; multiple orthogonal approaches across two laboratories\",\n      \"pmids\": [\"26744461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A PKC-MARCKS-PI3K regulatory module links leading-edge Ca2+ and PIP3 signals in live macrophages; PKC and PI3K are both essential for the positive feedback loop; activators stimulate leading-edge PKC activity, MARCKS membrane displacement, and increased PIP3, while inhibitors trigger the opposite.\",\n      \"method\": \"Live-cell biosensors (AKT-PH-mRFP for PIP3, CKAR for PKC activity, MARCKSp-mRFP for MARCKS membrane binding, leading-edge area), pharmacological inhibitors (wortmannin, EGTA, Go6976), PDGF and ATP stimulation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — four orthogonal live-cell biosensors in macrophages with activators and inhibitors testing distinct pathway nodes; consistent with the in vitro reconstitution data from the same group\",\n      \"pmids\": [\"29715315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Phosphorylated MARCKS (pMARCKS) functions as an E2F-1 cofactor to regulate SKP2 transcription, thereby facilitating cell-cycle progression by suppressing p27Kip1 and promoting Cyclin E/CDK2 activity in multiple myeloma.\",\n      \"method\": \"iTRAQ mass spectrometry, RNAi knockdown, pharmacological inhibition (enzastaurin), co-factor/transcription assay, cell-cycle analysis, xenograft model\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological manipulation with defined molecular mechanism (E2F-1 co-factor); single laboratory\",\n      \"pmids\": [\"25179733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MARCKS is acetylated by the acetyltransferase Tip60 at lysine 165 under high glucose conditions, and this acetylation is a prerequisite for subsequent PKC-mediated phosphorylation; SIRT2 deacetylates MARCKS and reverses this modification; phosphorylated/translocated MARCKS leads to mitochondrial abnormalities and ER stress.\",\n      \"method\": \"Co-IP, acetyltransferase assay with Tip60, SIRT2 deacetylation assay, phosphorylation-dead MARCKS (PD-MARCKS) expression, SIRT2 rescue in neuroepithelium, organelle stress assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — identified writer (Tip60) and eraser (SIRT2) for MARCKS acetylation with functional consequence established via phosphorylation-dead mutant and genetic rescue; multiple orthogonal methods\",\n      \"pmids\": [\"30655546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ENaC activity is regulated by calpain-2 proteolysis of MARCKS; calpain-2 cleaves MARCKS (but not ENaC subunits) in a Ca2+-dependent manner; calpain-2 inhibition reduces the association between ENaC and MARCKS and decreases ENaC open probability.\",\n      \"method\": \"In vitro calpain-2 cleavage assay with recombinant fusion proteins, pharmacological calpain-2 inhibition, single-channel patch-clamp, transepithelial current, sucrose gradient fractionation, co-immunoprecipitation\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct enzyme substrate reconstitution (recombinant proteins + Ca2+), complemented by pharmacological inhibition and electrophysiological readouts; multiple orthogonal methods\",\n      \"pmids\": [\"28468944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Platelet secretion (serotonin release) induced by phorbol esters requires MARCKS phosphorylation; a peptide corresponding to the MARCKS phosphorylation site domain (MPSD) blocks MARCKS phosphorylation and serotonin secretion in permeabilized platelets without affecting pleckstrin or myosin light chain phosphorylation.\",\n      \"method\": \"Permeabilized platelet secretion assay, MARCKS phosphorylation assay, specific phosphorylation site domain peptide (MPSD) vs. alanine-substituted control peptide, time-course analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific phosphorylation site peptide with control (Ala-MPSD) plus parallel time-course and specificity controls; single laboratory\",\n      \"pmids\": [\"10648401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PKCβ-MARCKS signaling is required for angiotensin II-stimulated vesicular trafficking along neurites in neurons; antisense knockdown of PKCβ or MARCKS blocks translocation of dopamine-β-hydroxylase-GFP-labeled vesicles from cell body to neurites.\",\n      \"method\": \"Real-time confocal microscopy of GFP-tagged vesicles, antisense oligonucleotides to PKCβ and MARCKS, PKC activators (PMA, carbachol, angiotensin II)\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live-cell imaging with antisense knockdown of two pathway components; single laboratory\",\n      \"pmids\": [\"11882609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Protein phosphatase-1 (PP1)-mediated dephosphorylation of MARCKS promotes its translocation to the plasma membrane during myoblast fusion; phosphorylation-preventing MARCKS mutation promotes fusion, while myristoylation-deficient MARCKS (which cannot reach the membrane) impairs myoblast fusion.\",\n      \"method\": \"Okadaic acid and tautomycin (PP inhibitors), PP1 identification by dephosphorylation assay, MARCKS phosphorylation mutants (non-phosphorylatable and myristoylation-deficient), cell fusion assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic dissection of PP1 role with defined MARCKS mutants; single laboratory\",\n      \"pmids\": [\"12045217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PKCε specifically phosphorylates MARCKS in cardiomyocytes; constitutively active PKCε increases phospho-MARCKS, dominant-negative PKCε reduces it and prevents co-localization of pMARCKS with F-actin; overexpression of wild-type MARCKS increases FAK phosphorylation and cardiomyocyte spreading, while non-phosphorylatable MARCKS blocks these effects.\",\n      \"method\": \"Adenoviral overexpression of wild-type, constitutively active, dominant-negative PKCε/δ/α, and GFP-tagged MARCKS mutants in neonatal and adult rat ventricular myocytes; immunofluorescence; FAK phosphorylation assay; cell area measurement\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific PKC dissection with multiple MARCKS mutants and functional readouts; single laboratory\",\n      \"pmids\": [\"17157309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PP2A interacts with MARCKS and is the dominant phosphatase for MARCKS after bradykinin-induced transient phosphorylation; this transient MARCKS phosphorylation (via PKC-RhoA/ROCK cascade) is required for bradykinin-induced neurite outgrowth.\",\n      \"method\": \"PP2A inhibitors (calyculin A, fostriecin), co-immunoprecipitation of PP2A with MARCKS, GST pull-down, SH-SY5Y cells expressing wild-type and unphosphorylatable MARCKS, cell morphology analysis\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and phosphatase inhibitors plus MARCKS phosphorylation mutant with defined morphological readout; single laboratory\",\n      \"pmids\": [\"21448919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Phosphorylated MARCKS (at Ser159/163) directly binds to NF-κB-activating protein (NKAP); upon MARCKS phosphorylation, the MARCKS-NKAP interaction is inhibited, releasing NKAP and leading to NF-κB activation in lung cancer cells.\",\n      \"method\": \"Functional proteomics (MARCKS interactome), co-immunoprecipitation, genetic knockdown, MPS peptide (phosphorylation inhibitor), phosphorylation site analysis (Ser159/163), cytokine measurement\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP interactome plus genetic and pharmacological validation; single laboratory\",\n      \"pmids\": [\"33754052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MARCKS knockdown in VSMCs arrests cell cycle at G0/G1 via p27kip1 nuclear trapping through decreased KIS expression; this is p27kip1-dependent (confirmed in p27kip1-/- mice) and rescued by KIS overexpression; in endothelial cells, MARCKS knockdown paradoxically increases KIS and proliferation.\",\n      \"method\": \"siRNA knockdown in VSMCs and ECs, p27kip1-/- mouse-derived VSMCs, adenoviral KIS overexpression, cell cycle analysis, p27kip1 phosphorylation and localization assays, murine aortic injury model with BrdU\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue (KIS overexpression) plus null cell validation in two cell types with in vivo confirmation; single laboratory\",\n      \"pmids\": [\"26528715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Membrane-tethered MARCKS suppresses BCR nanoclustering and tonic/chronic active BCR signaling by disturbing the interaction between cortical F-actin and the inner leaflet of the plasma membrane, thereby increasing BCR lateral mobility; genetically induced MARCKS loss increases AKT signaling and B-cell migratory capacity.\",\n      \"method\": \"Single-molecule tracking in live cells, MARCKS mutants (membrane-tethered and membrane-untethered), MARCKS knockout, BCR nanoclustering analysis, AKT phosphorylation assay, migration assay\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single-molecule tracking with defined MARCKS mutants and KO; multiple functional readouts; single laboratory\",\n      \"pmids\": [\"30209404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MCP-1-induced macrophage migration involves rapid MARCKS phosphorylation and translocation from plasma membrane to cytosol, accompanied by actin redistribution into cell protrusions; transient MARCKS-actin interaction during migration was detected biochemically.\",\n      \"method\": \"MANS peptide inhibition, confocal microscopy with fluorescent anti-MARCKS antibody and phalloidin, MARCKS phosphorylation/translocation assay, J774A.1 and primary mouse macrophage migration assay\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific peptide inhibitor and confocal imaging with biochemical co-localization; single laboratory\",\n      \"pmids\": [\"22623357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TRIM1-269aa (encoded by circTRIM1) enhances the interaction between MARCKS and calmodulin, thereby promoting calmodulin-dependent translocation of MARCKS from the membrane, which further activates the PI3K/AKT/mTOR pathway in TNBC cells.\",\n      \"method\": \"Co-immunoprecipitation of MARCKS-calmodulin complex with/without TRIM1-269aa, MARCKS translocation assay, PI3K/AKT/mTOR pathway readout\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP in cell lines; mechanistic claim about MARCKS regulation supported only by co-IP with limited validation of the MARCKS-specific step\",\n      \"pmids\": [\"38755678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"WNT5A-induced PKC activation leads to increased MARCKS expression and phosphorylation; MARCKS phosphorylation at the leading edge is required for WNT5A-mediated melanoma cell invasion, as demonstrated by siRNA-mediated MARCKS knockdown and a MARCKS phosphorylation inhibitor peptide.\",\n      \"method\": \"Recombinant WNT5A treatment, WNT5A siRNA, MARCKS siRNA, MARCKS phosphorylation inhibitor peptide, confocal imaging of pMARCKS at leading edge, invasion assay\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (siRNA) and pharmacological (phosphorylation inhibitor) approaches converge on same invasion phenotype; single laboratory\",\n      \"pmids\": [\"32033033\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MARCKS is a myristoylated, intrinsically disordered PKC substrate that shuttles between the inner plasma membrane leaflet and cytosol via a 'myristoyl-electrostatic switch': in the unphosphorylated state, its basic effector domain electrostatically anchors it to acidic phospholipids (especially PIP2), where it crosslinks F-actin, sequesters PIP2 (thereby inhibiting PI3K/PIP3 production), binds calmodulin, and stabilizes cortical cytoskeletal structures; upon phosphorylation at Ser152/156/163 by PKC (with δ- and ε-isoforms being cell-type-specific writers), the effector domain's affinity for membranes and calmodulin falls ~200-fold, releasing sequestered PIP2 to feed the PI3K–PIP3 amplification module at the leading edge, allowing calmodulin-dependent enzymes to activate, and routing MARCKS to lysosomes (via cathepsin B cleavage) or to the cytosol; Tip60 acetylation at K165 is a prerequisite for phosphorylation, reversed by SIRT2, while PP1 and PP2A dephosphorylate MARCKS to return it to the membrane; these reversible modifications collectively regulate F-actin dynamics, cell spreading, migration, vesicular trafficking, mucin secretion, ENaC activity, BCR signaling, and brain development.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MARCKS is a myristoylated, calmodulin- and phospholipid-binding protein that couples the cortical actin cytoskeleton to the inner leaflet of the plasma membrane and acts as a reversible, PKC-controlled relay in motility, secretion, and signaling [#0, #6, #11]. It crosslinks F-actin and tethers to acidic phospholipids through two cooperating modules—an N-terminal myristoyl moiety and a basic effector domain—and both actin crosslinking and membrane binding are switched off by PKC phosphorylation of the effector domain and by Ca2+-calmodulin binding [#0, #1, #2, #8]. This 'myristoyl-electrostatic switch' drives bi-directional cycling between membrane and cytosol: phosphorylation (followed by PP1/PP2A dephosphorylation) governs translocation, lysosomal targeting via cathepsin B cleavage, and the membrane-versus-cytosol balance required for cell spreading, adhesion, and stress-fiber maturation [#4, #7, #9, #11, #30]. At the membrane MARCKS sequesters PIP2 and restrains PI3K, so PKC-driven release of PIP2 recruits and activates PI3K to form a leading-edge Ca2+–PKC–MARCKS–PIP2–PI3K amplification module that controls PIP3 signaling and directed migration [#22, #24]. Through this switch MARCKS regulates diverse processes including airway mucin secretion via PKCδ, neutrophil and macrophage migration, megakaryocyte proplatelet formation, and ENaC channel activity through PIP2 availability [#12, #13, #17, #20, #23, #36]. MARCKS is also acetylated at Lys165 by Tip60 as a prerequisite for phosphorylation and deacetylated by SIRT2, and it binds LPS through an effector-domain heptapeptide to dampen TLR4 signaling [#18, #26]. MARCKS is required for normal brain development, where membrane association mediated by its myristoylation domain governs radial glial progenitor placement [#5, #14].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Established that PKC phosphorylation of the effector domain is a molecular switch controlling calmodulin affinity, explaining how MARCKS could gate calmodulin-dependent enzyme activation.\",\n      \"evidence\": \"Synthetic effector-domain peptide phosphorylated by PKC in vitro with calmodulin binding and CaM-enzyme activity assays\",\n      \"pmids\": [\"2002042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Done with a 25-mer peptide, not full-length protein in cells\", \"Numbering (Ser8/Ser12) of the peptide not yet mapped to physiological residues\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Identified MARCKS as a regulated F-actin crosslinker, linking it physically to the cortical cytoskeleton and showing both PKC and calmodulin inhibit this activity.\",\n      \"evidence\": \"In vitro F-actin crosslinking assay with PKC phosphorylation and calmodulin binding\",\n      \"pmids\": [\"1560845\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crosslinking shown in vitro; cellular consequences not yet established\", \"No structural model of the actin-binding interface\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Defined the bipartite membrane-anchoring mechanism (myristoyl plus basic domain) and showed phosphorylation lowers phospholipid affinity, giving a physical basis for membrane release.\",\n      \"evidence\": \"Purified MARCKS and effector peptide binding to defined liposomes with PKC phosphorylation; mapping of PKC sites to Ser152/156/163 by tryptic analysis\",\n      \"pmids\": [\"8486722\", \"8422248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phospho-site mapping from a single laboratory\", \"Lipid binding measured on planar/vesicle systems, not native membranes\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Identified PP1/PP2A as the phosphatases that reverse PKC phosphorylation, completing the reversible cycle that returns MARCKS to the membrane.\",\n      \"evidence\": \"Cell-free phosphatase assays and okadaic acid treatment in Swiss 3T3 cells\",\n      \"pmids\": [\"8262213\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific phosphatase responsible in vivo not resolved among PP1/PP2A/PP2C\", \"No demonstration of physiological membrane re-targeting at this stage\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrated that phosphorylation is required for MARCKS translocation and lysosomal targeting in cells, and that MARCKS is essential for brain development.\",\n      \"evidence\": \"Phosphorylation-deficient mutants with immuno-EM/fractionation in fibroblasts; knockout mice with developmental phenotyping\",\n      \"pmids\": [\"7720702\", \"7862670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular targets mediating the developmental phenotype not yet defined\", \"Route to lysosomes mechanistically incomplete\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identified cathepsin B as the MARCKS-cleaving enzyme and showed the myristoyl-electrostatic switch is required for cell spreading and adhesion.\",\n      \"evidence\": \"Cathepsin B co-purification and cell-free cleavage with CA074-Me; switch-mutant expression in fibroblasts with morphology and adhesion assays\",\n      \"pmids\": [\"9295331\", \"9259558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of the p40 cleavage product unknown\", \"Switch-mutant phenotype from single laboratory\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Refined the calmodulin interaction by showing the myristoyl group itself contributes phosphorylation-independent, ionic-strength-independent calmodulin binding.\",\n      \"evidence\": \"Calmodulin-agarose chromatography and dansyl-calmodulin assays with myristoylated vs non-myristoylated MARCKS and N-terminal peptides\",\n      \"pmids\": [\"14506265\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of N-terminal CaM binding versus effector-domain binding unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Separated MARCKS's developmental functions by domain, showing membrane association via myristoylation (not phosphorylation) drives radial glial progenitor placement.\",\n      \"evidence\": \"Knockout mice rescued with phosphorylation-deficient and myristoylation-deficient mutants\",\n      \"pmids\": [\"19666823\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors in radial glia not identified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined MARCKS as a PIP2-sequestering regulator of ion channels and a lipid/curvature sensor, and as an LPS-binding modulator of TLR4 signaling.\",\n      \"evidence\": \"FRET/patch-clamp on ENaC; curvature-defined vesicle binding; NMR of the LPS-binding heptapeptide with KO MEFs\",\n      \"pmids\": [\"22791334\", \"23075500\", \"22427633\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"ENaC and lipid-sensing data each from single laboratories\", \"Whether LPS binding occurs at physiological concentrations in vivo unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Reconstituted the PKC–MARCKS–PIP2–PI3K leading-edge amplification module at single-molecule resolution and confirmed it as a positive-feedback loop in live macrophages.\",\n      \"evidence\": \"Single-molecule fluorescence on lipid bilayers; live-cell biosensors with activators/inhibitors in macrophages\",\n      \"pmids\": [\"27119641\", \"29715315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution relative to other PIP2 effectors in vivo not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified an acetylation layer upstream of phosphorylation, with Tip60 acetylating Lys165 as a prerequisite for PKC phosphorylation and SIRT2 reversing it.\",\n      \"evidence\": \"Tip60 acetyltransferase and SIRT2 deacetylation assays with phosphorylation-dead mutant and genetic rescue\",\n      \"pmids\": [\"30655546\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of acetylation control beyond high-glucose neuroepithelium not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended the calmodulin-translocation axis to disease, implicating a circRNA-encoded peptide in enhancing MARCKS-calmodulin binding and PI3K/AKT/mTOR activation.\",\n      \"evidence\": \"Co-IP of MARCKS-calmodulin with/without TRIM1-269aa and pathway readouts in TNBC cells\",\n      \"pmids\": [\"38755678\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single Co-IP with limited validation of the MARCKS-specific step\", \"Direct effect on MARCKS translocation not biochemically isolated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the membrane/cytosol cycle, acetylation-priming, calmodulin extraction, and protease cleavage are integrated and spatially coordinated to produce tissue-specific outputs remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No integrated structural model of full-length MARCKS at membranes\", \"Relative in vivo contributions of cathepsin B and calpain-2 cleavage unknown\", \"Cause of opposite migration/proliferation outcomes across cell types unexplained\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [0, 11]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [1, 15, 22]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 22, 17]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 35]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 4, 24]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [4, 16, 36]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [4, 7]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 31]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [22, 24, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [18, 35]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [4, 19, 29]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CALM1\", \"PRKCD\", \"PRKCE\", \"PI3K\", \"CTSB\", \"CAPN2\", \"NKAP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}